To guarantee pharmaceutical safety, the pharmaceutical industry has long relied on blood harvested from horseshoe crabs, an ancient marine organism, to detect endotoxins in pharmaceuticals. However, with the explosive surge in demand for vaccines and other biological products, horseshoe crab blood is being consumed far faster than the species can naturally replenish its population, rendering this resource increasingly scarce.

Critically, the traditional Limulus Amebocyte Lysate (LAL) assay is susceptible to interference from 1,3-β-D-glucan in samples. This triggers additional testing and investigative work, delays batch release timelines, and drives up costs. As such, the industry demands a novel endotoxin testing method that delivers high efficiency, accuracy, and sustainability, while reducing reliance on horseshoe crab resources.

01 Recreate the Classic, Surpass the Original

Rather than adopting an entirely new technical route, recombinant horseshoe crab reagent utilizes genetic engineering to precisely recombinantly express three key enzymes: Factor C, Factor B, and Pro-clotting Enzyme, which are then lyophilized in strict accordance with their natural physiological ratios.

While retaining the high specificity and sensitivity of native LAL reagents, the platform integrates turbidimetric kinetic colorimetry. It delivers test results as reliable as those from native reagents, enables real-time monitoring of reaction progression, and clearly identifies anomalies such as sample interference or omitted reagent addition. This dual advantage ensures both dependable results and fully controllable testing workflows.

02 Fully Benchmarked for Seamless Replacement

HZSKBIO^Ⓡ rCR reagents deliver performance fully matching native LAL! The linear range uniformly covers 0.005–5 EU/mL, with sensitivity and reliability perfectly aligned with conventional lysate reagents. Laboratories may reuse existing LAL validation protocols without method revisions, offering a straightforward, reliable one-to-one replacement solution.

03 Eliminate Batch-to-Batch Fluctuations for "Copy-Paste" Consistent Performance

In precise quantitative testing, minor fluctuations in reagent performance can compromise result integrity. We prioritize this core concern by leveraging highly stable, tightly controlled genetic engineering manufacturing workflows, which deliver exceptional intra-batch and inter-batch consistency for recombinant cascade reagents at the source.

• Outstanding intra-batch consistency: Ultra-low CV values for repeated testing within a single reagent lot, ensuring precise, trustworthy individual test runs.

• Superior inter-batch consistency: Uniform performance across separate production batches, eliminating systematic errors and repeat testing expenses triggered by reagent lot changes.

  
  

04 Broad Applicability Supported by Authoritative Verification

Third-party authoritative validation data confirms the following key findings:

1. For endotoxin testing across diverse sample matrices, rCR generates results fully consistent with native LAL reagents, with recovery rates complying with pharmacopoeial standards. Its performance matches or even exceeds that of natural horseshoe crab lysate.

2. The rCR method exhibits excellent inter-laboratory reproducibility: consistent sample dilution factors and test readouts are achieved, with recovery rates meeting pharmacopoeial requirements and narrow fluctuation ranges.

05 Streamlined Replacement Workflow to Accelerate Project Progress

Recommendation: Laboratories first evaluate the full validation data package supplied by the reagent vendor, then conduct suitability testing using their own product matrices to confirm method compatibility.

HZSKBIO^Ⓡ provides comprehensive supporting validation datasets to fast-track method conversion, drastically cutting validation timelines and costs for a smooth, efficient reagent transition.